MedTrace Logo

A First Time In Human Study To Assess The Compound GSK615915

NCT00400660 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-09-29

No results posted yet for this study

Summary

GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.

Conditions

  • Bronchospasm

Interventions

DRUG

GSK615915A

GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.

DRUG

Placebo

Subjects will also receive placebo inhaler.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-11-23
Primary Completion
2006-07-03
Completion
2006-07-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400660 on ClinicalTrials.gov